Frontlight ResearchEarly access
CompletedPhase 2
Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial
Key facts
- Who runs it
- University of Colorado, Denver
- Where
- Aurora, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 43 people enrolled
- Started
- 11 Apr 2023
- Ended
- 7 Jul 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cannabidiol
- Placebo
- Record updated
- 17 December 2025
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Ability to provide valid informed consent
- 18-60 years old
- Current or history of TBI as identified by the Ohio Identification Method
- TBI severity is mild or moderate based on the VA/DoD Classification of TBI Severity
- TBI event must have resulted in hospital evaluation (emergency department or other hospital-based assessment) or evaluation within a clinical setting, except in cases in which the TBI was acquired in a military deployment context in which medical services were not immediately available
- Ongoing neuropsychiatric symptoms (i.e., depressive, anxiety, pain, cognitive complaints, or sleep complaints) that are plausibly associated with TBI and not better accounted for by co-occurring medical or psychological health conditions
- Not currently in another treatment study for TBI-related symptoms or co-occurring medical or psychological health conditions
- Co-occurring treatments must be stable in type, dose, and frequency for the four weeks preceding study enrollment and participants must commit to making no changes in these co-occurring treatments during the study
Who cannot take part
- Reported use of other drugs (cocaine, opiates, methamphetamine, MDMA) in the past 60 days or test positive on a urine test for those drugs of abuse at baseline
- History of autism spectrum disorders, intellectual disability, and/or serious neurological or central nervous system disease that would be expected to affect cognition (e.g., epilepsy, tumors, multiple sclerosis)
- Current or lifetime diagnosis of a schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic), eating disorders, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revised (DSM-5-TR, APA 2022)
- Meets criteria for major depressive episode as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revised (DSM-5-TR, APA 2022) and with a Beck Depression Inventory-2 score > 24
- History of significant systemic illness or unstable medical condition
- Alcohol use disorder score of 5 or greater, or substance use disorder, based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revised (DSM-5-TR, APA 2022), in the six months preceding study enrollment
- Current diagnosis of a seizure disorder or epilepsy
- Currently taking medications known to be contraindicated with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide, clobazam, lamotrigine, valproate)
- Liver function enzymes (AST, ALT) that are greater than 2x normal
- Currently incarcerated, paroled, or on probation
- Participant has retained an attorney in relation to the TBI
- Pregnant at the time of study enrollment or unwilling to commit to the use of two forms of contraception throughout the duration of the study
- Vision, hearing, or communication impairments that preclude valid completion of study assessments
- Evidence of poor effort (TOMMe < 8) on neuropsychological testing at baseline/Week 0
- Current suicidal ideation, as indicated by Beck Depression Inventory-2 item #9 score > 0, or C-SSRS endorsement of item #2, or verbal or written report of current suicidal ideation by the participant to any study team member
- Report using cannabis once daily or more than once daily over the last 12 months
- Report current use of CBD for medical reasons or TBI symptoms
Where in United States
- University of Colorado AnschutzAurora, United States
About the trial
What the trial wants to find out
This is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to improve cognition and traumatic brain injury-related symptoms. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.
The 3 groups in the trial
- Full Spectrum CannabidiolExisting treatment, for comparison
Full Spectrum Cannabidiol (\<0.3% THC) Oral softgel capsule, 210mg/day
Treatment: Cannabidiol
- Broad Spectrum CannabidiolExisting treatment, for comparison
Broad Spectrum Cannabidiol (0.0% THC) Oral softgel capsule, 210mg/day
Treatment: Cannabidiol
- Hemp Seed OilPlacebo, for comparison
Placebo Oral softgel capsule, 210mg/day
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 December 2025